T/NK cell type chronic active Epsteine - Barr virus disease in adults: An underlying condition for Epstein - Barr virus-associated T/NK-cell lymphoma

Journal of Clinical Pathology

Volumn 65, Issue 3, 2012, Pages 278-282

  Isobe, Yasushi ^a   Aritaka, Nanae ^a   Setoguchi, Yasuhiro ^b   Ito, Yoshinori ^c   Kimura, Hiroshi ^c   Hamano, Yasuharu ^a   Sugimoto, Koichi ^a   Komatsu, Norio ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE;

ADULT; AGGRESSIVE NK CELL LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD; CHRONIC ACTIVE EPSTEIN BARR VIRUS DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; EPSTEIN BARR VIRUS INFECTION; FEMALE; HEPATITIS; HUMAN; HUMAN CELL; HYPERSENSITIVITY; INSECT BITE; INTERSTITIAL PNEUMONIA; LABORATORY TEST; MALE; NATURAL KILLER CELL; NEPHRITIS; NK T CELL LYMPHOMA; PRIORITY JOURNAL; T LYMPHOCYTE; UVEITIS; VIRUS LOAD;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BIOPSY; BLOTTING, SOUTHERN; CHRONIC DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; KILLER CELLS, NATURAL; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; T-LYMPHOCYTES; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84857369973     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200523     Document Type: Article

References (12)

1. Thorley-Lawson DA, Gross A. Persistence of the Epstein - Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328-37.
2. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein - Barr virus infection. Blood 2001;98:280-6.
3. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein - Barr virus infection. Am J Hematol 2005;80:64-9.
4. Cohen JI, Jaffe ES, Dale JK, et al. Chracterization and treatment of chronic active Epstein - Barr virus disease: a 28 year experience in the United States. Blood 2011;117:5835-49.
5. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: WHO, 2008.
6. Ohshima K, Kimura H, Yoshino T, et al. Proposed categorization of pathological status of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fluminant EBV T-LPD. Pathol Int 2008;58:209-17.
7. Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein - Barr virus infection. J Infect Dis 2005;191:531-9.
8. Katano H, Ali MA, Patera AC, et al. Chronic active Epstein - Barr virus infection associated with mutations in perforin that impair its maturation. Blood 2004;103:1244-52.
9. Isobe Y, Sugimoto K, Yang L, et al. Epstein - Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res 2004;64:2167-74.
10. Isobe Y, Sugimoto K, Aritaka N, et al. Epstein - Barr virus infection of peripheral blood T cells (in Japanese). Rinsho Ketsueki 2007;48:1145.
11. Hudnall SD, Ge Y, Wei L, et al. Distribution and phenotype of Epstein - Barr virusinfected cells in human pharyngeal tonsils. Mod Pathol 2005;18:519-27.
12. Kawa K, Sawada A, Sato A, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transpl 2011;46:77-83.